Cartesian Therapeutics Stock (NASDAQ:SELB)


RevenueOwnershipFinancialsChart

Previous Close

$0.96

52W Range

$0.79 - $1.99

50D Avg

$1.10

200D Avg

$1.19

Market Cap

$135.20M

Avg Vol (3M)

$634.42K

Beta

0.83

Div Yield

-

SELB Company Profile


Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

64

IPO Date

Jun 22, 2016

Website

SELB Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 19
Grant$100.00K

Fiscal year ends in Dec 23 | Currency in USD

SELB Financial Summary


Dec 23Dec 22Dec 21
Revenue-$110.78M$85.08M
Operating Income$-86.42M$14.54M$-4.60M
Net Income$-219.71M$35.38M$-25.69M
EBITDA$-86.42M$16.16M$-4.58M
Basic EPS-$0.24$-0.22
Diluted EPS-$0.10$-0.22

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q1 23May 04, 23 | 7:06 PM
Q4 22Mar 02, 23 | 3:16 PM
Q3 22Nov 05, 22 | 2:18 AM

Peer Comparison


TickerCompany
CKPTCheckpoint Therapeutics, Inc.
GMDAGamida Cell Ltd.
RVPHReviva Pharmaceuticals Holdings, Inc.
FBIOFortress Biotech, Inc.
CRVSCorvus Pharmaceuticals, Inc.
RIGLRigel Pharmaceuticals, Inc.
RNAZTransCode Therapeutics, Inc.
KODKodiak Sciences Inc.
EYENEyenovia, Inc.
IMMPImmutep Limited
GERNGeron Corporation
MBIOMustang Bio, Inc.
CGTXCognition Therapeutics, Inc.
CDTXCidara Therapeutics, Inc.